Skip to content

Effectiveness and safety of tirofiban in the treatment of ischemic stroke

A strategic study on the use of tirofiban in endovascular therapy for acute ischemic stroke

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044191
Enrollment
Unknown
Registered
2021-03-12
Start date
2022-01-01
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Interventions

1:do not use tirofiban
2:full dose tirofiban
3:2/3 full dose tirofiban
4:1/3 full dose tirofiban

Sponsors

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Above the age of 18 years; (2) In stroke patients with great vessel occlusion, the onset of anterior circulation occlusion was less than 6 h, and the onset of anterior circulation occlusion was less than 6-24 h after rigorous imaging screening, the onset of posterior circulation great vessel occlusion was less than 24 h; (3) CT excluded intracranial hemorrhage and subarachnoid hemorrhage; (4) Acute ischemic stroke, imaging examination confirmed as great vessel occlusion; (5) Informed consent signed by the patient or legal representative.

Exclusion criteria

Exclusion criteria: (1) If arterial thrombolysis is performed, the contraindication criteria for intravenous thrombolysis are referred. (2) active bleeding or known bleeding tendency; (3) serious heart, liver and renal insufficiency; (4) Blood glucose 22.2 mmol/L; (5) Severe hypertension that cannot be controlled by drugs.

Design outcomes

Primary

MeasureTime frame
NIHSS??;Intracranial bleeding;

Secondary

MeasureTime frame
mRS??;thrombolysis in Cerebral Infarction classification;

Countries

China

Contacts

Public ContactXu Danhua

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

471689939@qq.com+86 17858840199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026